Stock Titan Trading tools for traders and investors.

-

04:29:40 PM

Last EDIT Stock Market News

EDIT - Editas Medicine Inc

02/25/21 7:00 AM

Nasdaq : EDIT

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board of Directors Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10

RHEA-AI

very positive

02/18/21 4:02 PM

Nasdaq : EDIT

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth

RHEA-AI

neutral

02/08/21 8:00 AM

Nasdaq : EDIT

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective

RHEA-AI

very positive

01/20/21 10:30 PM

Nasdaq : EDIT

Editas Medicine Announces Pricing of Offering of Common Stock

Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter

RHEA-AI

neutral

01/19/21 4:01 PM

Nasdaq : EDIT

Editas Medicine Announces Offering of Common Stock

Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a

RHEA-AI

neutral

01/11/21 6:05 AM

Nasdaq : EDIT

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase 1/2 RUBY trial and plans to file IND for the treatment of beta-thalassemia CAMBRIDGE, Mass., Jan. 11, 2021

RHEA-AI

very positive

01/11/21 6:02 AM

Nasdaq : EDIT

Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has

RHEA-AI

neutral

01/11/21 6:00 AM

Nasdaq : EDIT

Editas Medicine Announces Transition of Chief Scientific Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is

RHEA-AI

very positive

01/04/21 4:05 PM

Nasdaq : EDIT

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m.

RHEA-AI

neutral

12/17/20 4:05 PM

Nasdaq : EDIT

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. Dr. Chatterjee is an accomplished biopharmaceutical executive with more than 30

RHEA-AI

very positive